Through step down subsidiary Auro Vaccines LLCAurobindo Pharma announced that Auro Vaccines LLC, 100% subsidiary of Aurobindo Pharma USA Inc., which in turn is 100% subsidiary of the Company, has entered into a definitive agreement to acquire certain business assets from Profectus BioSciences Inc., USA., a clinical-stage vaccine development company.
The acquisition provides access to proprietary and innovative technology platforms for prophylactic use and therapeutic use along with Global R&D center. The acquisition will also lead to enhancement of R&D capabilities and expertise in developing newer vaccines from basic discovery research into FDA-approved product.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)